Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (NASDAQ: VCYT) is a leader in genomic diagnostics, developing advanced solutions that transform patient care through precision medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, clinical advancements, and strategic initiatives.
Access official press releases, earnings reports, and regulatory filings in one centralized location. Track developments across key areas including oncology testing innovations, global expansion efforts, and partnerships with leading research institutions. Our curated collection ensures you stay informed about milestones that shape VCYT’s role in advancing evidence-based diagnostic technologies.
Discover updates on new product clearances, peer-reviewed study publications, and executive leadership announcements. This resource is designed to support data-driven decision-making for stakeholders monitoring the evolving landscape of molecular diagnostics. Bookmark this page for direct access to primary source materials and analysis of Veracyte’s market position.
Veracyte (VCYT) announced that 18 abstracts featuring its Decipher Prostate and Bladder Genomic Classifiers will be presented at the AUA 2025 conference in Las Vegas. The presentations will showcase new data from clinical trials and insights derived from the whole-transcriptome-based Decipher GRID research tool.
Key presentations include research on immune infiltration signatures in bladder cancer treatment response, transcriptomic examination of Grade Group 1 prostate cancer, and regional prostate cancer heterogeneity analysis. Dr. Vignesh Packiam will present findings on therapy response in high-risk non-muscle-invasive bladder cancer, while Dr. Nicole Handa will discuss molecular features of Grade Group 1 prostate cancer. Dr. Deepak Kapoor's research focuses on regional transcriptomic differences in prostate cancer patients.
Veracyte (VCYT) announced the inclusion of its Decipher Prostate Genomic Classifier data in the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Program's new specialized database. This integration will allow researchers to analyze Decipher Prostate test results alongside real-world patient outcomes, cancer characteristics, treatment protocols, and demographics.
The SEER database linkage encompasses over 560,000 prostate cancer cases diagnosed from 2010 to 2018. The Decipher Prostate test has been available for radical prostatectomy specimens since 2013 and biopsy tissue since 2016. This collaboration reinforces Veracyte's commitment to building clinical evidence and advancing cancer research.
Veracyte (VCYT) has scheduled the release of its first quarter 2025 financial results after market close on Wednesday, May 7, 2025. The cancer diagnostics company will follow the release with a conference call and webcast at 4:30 p.m. Eastern Time, where management will discuss the financial performance and provide a business update.
Investors and interested parties can access the live webcast through the company's website, with a replay being made available afterward at the investor relations section.
Veracyte (VCYT) announced new data demonstrating superior accuracy of its whole-genome sequencing (WGS)-based minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer. The findings from the TOMBOLA trial, involving 100 patients, showed the platform detected cancer recurrence with higher specificity (88%) compared to ddPCR (62%), while maintaining equivalent negative predictive value (~96%).
The study revealed that Veracyte's MRD testing platform detected cancer recurrence 93 days earlier than standard imaging. The platform combines WGS and artificial intelligence to detect residual cancer in blood samples, requiring less blood and delivering faster results compared to traditional methods.
The company plans to launch its first MRD test for muscle-invasive bladder cancer in the first half of 2026. The platform establishes patient-specific genomic signatures by analyzing cancer mutations in tumor tissue and blood samples, enabling ongoing monitoring of tumor progression throughout treatment and follow-up care.
Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer. The company will also present independent performance data from a large, multicenter trial (TOMBOLA) supporting their minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer.
Dr. Philip Febbo, Veracyte's chief scientific officer and chief medical officer, highlighted how their whole-transcriptome approach enables partnerships with researchers to gain new insights into cancer biology. The company plans to launch an MRD test for muscle-invasive bladder cancer next year, utilizing their whole-genome approach.
Veracyte (VCYT) reported strong Q4 2024 financial results with total revenue increasing 21% to $118.6 million. Testing revenue grew 24% to $112.2 million, driven by impressive performance in Decipher (44% growth) and Afirma (4% growth) tests. Total test volume increased 22% to 41,271 tests.
For full-year 2024, total revenue rose 23% to $445.8 million, with testing revenue up 28% to $419.0 million. The company achieved net income of $24.1 million (5.4% of revenue) and adjusted EBITDA of $91.9 million (20.6% of revenue). Cash flow from operations was $75.1 million.
Looking ahead to 2025, Veracyte expects testing revenue between $470-480 million (12-15% growth) and adjusted EBITDA margin of approximately 21.6%. The company is evaluating its French subsidiary operations and considering potential divestiture or discontinuation of funding.
Veracyte (VCYT), a leading cancer diagnostics company, has announced its participation in two upcoming investor conferences in March. The company will present at the Raymond James 46th Annual Institutional Investors Conference in Orlando, FL on March 5th at 9:50 a.m. Eastern Time, and participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on March 11th at 8:40 a.m. Eastern Time.
Live audio webcasts of both presentations will be accessible through Veracyte's investor relations website. Replay recordings will remain available for 90 days following each presentation.
Veracyte (VCYT) presented new data at the 2025 ASCO Genitourinary Cancers Symposium demonstrating the effectiveness of its Decipher Prostate and Bladder tests in guiding cancer treatment. Key findings from 17 Decipher-focused abstracts showed that the Decipher Prostate Genomic Classifier can help identify patients who will benefit from pelvic nodal radiation therapy, while the Decipher Bladder test accurately identified less aggressive cancer cases based on molecular subtypes.
Additionally, research using Veracyte's Decipher GRID tool validated the PORTOS signature's ability to predict patient response to different radiation therapy dosages. The study, also published in Annals of Oncology, analyzed data from two Phase 3 trials, showing that patients with higher PORTOS scores significantly benefited from increased radiation doses in both salvage and definitive radiotherapy settings.
Veracyte (VCYT) announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium, demonstrating the effectiveness of its Decipher tests in guiding treatment decisions for prostate and bladder cancers. Key findings include the Decipher Prostate test's ability to inform treatment intensification strategies in salvage radiotherapy patients, and the Decipher Bladder test's accuracy in identifying favorable outcomes in bladder cancer patients.
The research presentations highlight the test's market leadership and inclusion in NCCN guidelines. Notable studies include validation of the PORTOS gene expression signature for predicting radiation therapy response, and a large-scale analysis showing Decipher Prostate's robust prognostic performance. The symposium will take place February 13-15 in San Francisco.
Veracyte (VCYT) announced new data supporting its Decipher Bladder Genomic Subtyping Classifier's effectiveness in improving bladder cancer staging. The study, published in European Urology Open Science, analyzed 226 patients from eight medical centers who underwent radical cystectomy without neoadjuvant chemotherapy.
Key findings showed that 33% of patients experienced pathological upstaging to non-organ-confined disease (19% for NMIBC and 53% for T2 disease). The study revealed that NMIBC patients with non-luminal tumors were more likely to be upstaged to MIBC compared to those with luminal tumors (51% vs. 32%). Additionally, patients with luminal-subtype bladder cancer demonstrated better overall survival based on a 33-month median follow-up.
This research adds to Veracyte's growing clinical evidence supporting its molecular tests in urology, where its Decipher Prostate Genomic Classifier is already the market leader.
